Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

Exclusion Criteria

• •positive results for insulin antibodies at screening
• •history of substance abuse or dependency within last 5 years
• •positive screening test for substance abuse
• •positive blood test for HIV, hepatitis B or hepatitis C antibody
• •fasting blood glucose of more than 126mg/dl
• •any existing medical conditions which might interfere with absoprtion, distribution, metabolism or excretion of study medication
• •history of bronchospastic disease(asthma), tachycardia, migraine headache, hypoglycemic episodes, jaundice, liver diseases, arterial hemorrhaging, severe hypertension or hypotension, cardiac abnormality, renal disease, allergies, unresolved psychiatric illness, drug-induced myopathy or any other clinically significant abnormality
• •has received investigational medications within 21 days prior to receiving the first dose of study medication
• •has taken or used any prescription medications within 21 days prior to receiving the first dose of study medication
• •has taken or used any OTC medications,vitamins or herbal and/or nutritional supplements within 10 days days prior to receiving the first dose of study medication
• •health that may be adversely affected by procedures or medications used in the study
• •unwillingness or inability to understand or to follow required study restrictions and procedures